FDA OKs Kcentra as antidote to warfarin

04/30/2013 | Los Angeles Times (tiered subscription model)

The FDA has approved the prothrombin complex concentrate Kcentra as a reversal agent for the anticoagulant warfarin. Health care providers will not need to match Kcentra with a patient's blood type, so it can be used faster than plasma to reverse the effects of warfarin. It cannot be used to reverse the effects of newer anticoagulants dabigatran and rivaroxaban.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC